Crucial US Panel to Cast Ballots on Changing Infant Hepatitis B Vaccine Guideline

Following a postponement and a particularly heated gathering, a national immunization advisory committee was expected to vote on Friday regarding a potential change to the longstanding recommendation that each baby be immunized against hepatitis B.

Heated Debate and a Postponed Decision

The initial day of the meeting on Thursday was marked by intense argument over curbing eligibility to the hepatitis B vaccine for babies and a choice to postpone the decision by a day to provide committee members extra time to examine the language. The panel, which advises the CDC on immunization practices, had put off the vote twice in the past.

“Is there any definitive data of injury of giving this shot before 30 days? Or is this speculation?” asked one committee member.

In reply, another attendee stated, “There is limited evidence about the long-term risk.”

Current Guidelines and Possible Consequences

The injection is presently advised for every newborn within 24 hours of delivery to prevent infection of hepatitis B, which can cause major damage to the liver. It has been given to over a billion individuals for more than three decades.

The meeting in Atlanta presented no recent proof of damage attributable to the vaccine. Specialists note any alteration to the current hepatitis B vaccine regimen could have profound and widespread repercussions for infant and child health in the United States.

Group Membership and Recent Changes

The advisory panel can only make recommendations to the leader of the CDC. The committee's composition has seen shifts in recent days, with the announcement that the committee’s most recent chair would leave for an official role and be replaced by a heart specialist who has been critical of other vaccines.

The board includes a number of immunization doubters who are in agreement with a desire to overhaul – and perhaps, in some cases, scrap – traditional vaccination recommendations.